🚨 New Pharmacotherapy for Obstructive Sleep Apnoea 🌙💊
In a landmark Phase 2 trial published in The Lancet, sultiame— a carbonic anhydrase inhibitor—showed dose-dependent reduction in AHI and improved nocturnal oxygenation in adults with moderate–severe OSA.
💡 Key insights:
• 298 participants across 5 European countries
• 200 mg daily delivered the best efficacy-to-tolerability balance
• Benefits most notable in sleepy phenotypes (ESS >10)
• Mild, dose-related paraesthesia most common AE
🔬 A promising step toward precision sleep medicine and pharmacologic options for patients who struggle with CPAP.
🌬️ Better breathing by night → brighter cognition by day.
📖 Lancet, 2025 — FLOW Study (Randerath et al.)
